A Phase 4, Open-label, Single Arm, 24-week, Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged ≥18 Years With Severe Eosinophilic asthMa (PRISM)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mepolizumab (Primary) ; Prednisolone; Prednisone; Salbutamol
Indications Asthma
Focus Adverse reactions
Acronyms PRISM
Sponsors GlaxoSmithKline; GSK

Most Recent Events

10 Sep 2024 Status changed from recruiting to completed.
27 Dec 2022 Planned End Date changed from 24 Nov 2023 to 23 Jan 2024.
02 Jun 2022 Planned End Date changed from 25 Apr 2023 to 24 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight